- Home
- MGNX vs LGI Comparison
MGNX vs LGI Comparison
Compare MGNX & LGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- LGI
- Stock Information
- Founded
- MGNX 2000
- LGI 2004
- Country
- MGNX United States
- LGI United States
- Employees
- MGNX N/A
- LGI N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- LGI
- Sector
- MGNX Health Care
- LGI
- Exchange
- MGNX Nasdaq
- LGI Nasdaq
- Market Cap
- MGNX 257.3M
- LGI 217.8M
- IPO Year
- MGNX 2013
- LGI N/A
- Fundamental
- Price
- MGNX $3.24
- LGI $16.69
- Analyst Decision
- MGNX Buy
- LGI
- Analyst Count
- MGNX 11
- LGI 0
- Target Price
- MGNX $8.57
- LGI N/A
- AVG Volume (30 Days)
- MGNX 770.4K
- LGI 41.1K
- Earning Date
- MGNX 11-05-2024
- LGI 01-01-0001
- Dividend Yield
- MGNX N/A
- LGI 7.10%
- EPS Growth
- MGNX N/A
- LGI N/A
- EPS
- MGNX N/A
- LGI N/A
- Revenue
- MGNX $141,329,000.00
- LGI N/A
- Revenue This Year
- MGNX $119.63
- LGI N/A
- Revenue Next Year
- MGNX N/A
- LGI N/A
- P/E Ratio
- MGNX N/A
- LGI N/A
- Revenue Growth
- MGNX 16.68
- LGI N/A
- 52 Week Low
- MGNX $2.95
- LGI $12.66
- 52 Week High
- MGNX $21.88
- LGI $16.68
- Technical
- Relative Strength Index (RSI)
- MGNX 37.79
- LGI 45.33
- Support Level
- MGNX $3.61
- LGI $16.31
- Resistance Level
- MGNX $5.10
- LGI $17.41
- Average True Range (ATR)
- MGNX 0.35
- LGI 0.25
- MACD
- MGNX -0.10
- LGI -0.01
- Stochastic Oscillator
- MGNX 4.62
- LGI 45.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt, and others.